About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of ...

ORLYNVAH™ is a novel oral penem antibiotic for the treatment of uUTI. ORLYNVAH™ possesses potent activity against species of Enterobacterales including those that encode extended spectrum ...

This week marks World Antimicrobial Resistance Awareness Week (WAAW) with several ASX stocks tackling superbugs in an effort ...

SIU research students are looking into ways to deactivate or stop virus-spreading germs with chemical technology in hopes it ...

A novel compound targets an essential transport system found only in disease-causing bacteria, leaving commensal bacteria ...

Austrian researchers evaluate MALDI-TOF MS assays for carbapenemase detection, assessing their reliability and practicality ...

The UK-based firm is developing its initial panel tests for Gram-negative bacteria with tests for Gram-positive bacteria and ...

Gram-negative bacteria pose a serious threat to global health because they can resist multiple antibiotics, making infections difficult to treat, according to the National Institutes of Health. In ...

Therapies beyond antibiotics such as vaccines and monoclonal antibodies have emerged as promising, preventative strategies for sepsis due to tuberculosis and anti-microbial resistant infections.

Refugees and asylum seekers might have an increased risk of antimicrobial resistance (AMR) carriage or infection due to several factors, with conflict and war known to accelerate the spread of AMR.

Patients had to have been given empiric antibiotic ... patients with Gram-positive bacteria, fungi, or polymicrobial infection that did not stratify results by Gram-negative bacteria were excluded.